Loading...
SRPT logo
SRPT
Sarepta Therapeutics

Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust

Published
22 Aug 24
Updated
27 Aug 25
AnalystConsensusTarget's Fair Value
US$23.92
23.3% undervalued intrinsic discount
27 Aug
US$18.34
Loading
1Y
-86.6%
7D
-8.6%

Author's Valuation

US$23.9

23.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates9

Shared on07 May 25
Fair value Decreased 86%

Read more

Shared on30 Apr 25
Fair value Decreased 1.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Decreased 3.87%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Decreased 3.57%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25
Fair value Decreased 4.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Increased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25
Fair value Decreased 1.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25
Fair value Decreased 3.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on10 Mar 25
Fair value Increased 297%

AnalystConsensusTarget has decreased revenue growth from 36.4% to 31.8% and decreased future PE multiple from 14.8x to 13.0x.

Read more